

KING PHARMACEUTICALS INC

Form 8-K/A

March 03, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K/A  
(Amendment No. 1)  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 12, 2006**

**King Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

<b>Tennessee</b> (State or other jurisdiction of incorporation)	<b>001-15875</b> (Commission File Number)	<b>54-1684963</b> (I.R.S. Employer Identification No.)
---	--	---

<b>501 Fifth Street, Bristol, Tennessee</b> (Address of principal executive offices)	<b>37620</b> (Zip Code)
---	----------------------------

Registrant's telephone number, including area code: **(423) 989-8000**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**EXPLANATORY NOTE**

This Amendment No. 1 to the Current Report on Form 8-K/A of King Pharmaceuticals, Inc. (the Company ) amends the Current Report on Form 8-K that was filed by the Company with the Securities and Exchange Commission (the Commission ) on February 17, 2006 (the Initial Form 8-K ). This Amendment No. 1 to the Initial Form 8-K is being filed to amend the statement in Item 1.01 of the Initial Form 8-K that copies of the Ramipril Patent License Agreement, the Ramipril Application License Agreement, the Product Supply Agreement and the Generic Distribution Agreement would be filed with the Company s Annual Report on Form 10-K for the twelve-month period ending December 31, 2005.

**ITEM 1.01 Entry into a Material Definitive Agreement.**

Copies of the Ramipril Patent License Agreement, the Ramipril Application License Agreement, the Product Supply Agreement and the Generic Distribution Agreement will be filed with the Company s Quarterly Report on Form 10-Q for the quarter ending March 31, 2006.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**King Pharmaceuticals, Inc.**

By: /s/ Brian A. Markison

Brian A. Markison  
President and Chief Executive Officer

Date: March 2, 2006